GO:1900158 negative regulation of bone mineralization involved in bone maturation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900158 describes any process that stops, prevents, or reduces the frequency, rate, or extent of bone mineralization specifically during bone maturation.
• This biological process is essential for proper skeletal development, preventing excessive or premature mineralization that could lead to bone fragility or abnormal skeletal architecture.
• Key negative regulators include transcription factors such as RUNX2, which can both promote and inhibit mineralization depending on context, and signaling molecules like vitamin A metabolites and FGF23.
• Dysregulation of this process is implicated in metabolic bone diseases, including osteoporosis, osteomalacia, and phenylketonuria-associated bone defects.
• CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, enable precise dissection of the genetic control of bone mineralization.
• Understanding GO:1900158 provides insights into therapeutic targets for skeletal disorders and bone regeneration strategies.
Description
Bone mineralization is a tightly regulated process that deposits hydroxyapatite crystals within the collagenous extracellular matrix, conferring mechanical strength to the skeleton. During bone maturation, mineralization must be carefully controlled to avoid pathological calcification or insufficient bone mass. The Gene Ontology term GO:1900158, negative regulation of bone mineralization involved in bone maturation, captures the biological processes that restrain or reduce the extent of mineralization specifically during the maturation phase of bone development. This term is distinct from general negative regulation of bone mineralization because it is temporally and contextually restricted to bone maturation, a critical window during skeletal development and growth. Researchers studying skeletal biology, osteoblast differentiation, and metabolic bone diseases require a precise understanding of GO:1900158 to interpret gene expression data, design functional experiments, and identify therapeutic targets. For example, Runx2, a master transcription factor for osteoblast differentiation, also plays a role in limiting mineralization at specific stages, illustrating the dual functions of key regulators. Similarly, vitamin A metabolites have been shown to negatively regulate osteoblast mineralization, highlighting the interplay between systemic signals and local bone maturation. This article provides a comprehensive, citation-backed overview of GO:1900158, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods including CRISPR-based models. All statements are grounded in published literature to ensure accuracy and utility for both human researchers and AI-driven knowledge retrieval systems.
negative regulation of bone mineralization involved in bone maturation At A Glance
| GO ID | GO:1900158 |
|---|---|
| GO term | negative regulation of bone mineralization involved in bone maturation |
| Ontology | biological_process |
| Synonym | down regulation of bone mineralization involved in bone maturation, down-regulation of bone mineralization involved in bone maturation, downregulation of bone mineralization involved in bone maturation, inhibition of bone mineralization involved in bone maturation |
| Major function | Restrains the deposition of mineral crystals in the bone extracellular matrix during bone maturation to prevent hypermineralization and maintain skeletal integrity. |
| Related biological process | Bone mineralization involved in bone maturation (GO:1900157), osteoblast differentiation, bone development. |
| Key regulators | RUNX2, vitamin A metabolites, FGF23, inflammatory macrophages via Notch signaling. |
| Disease relevance | Osteoporosis, osteomalacia, phenylketonuria-associated bone defects, ectopic calcification. |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, histological staining, micro-CT. |
What Is GO:1900158?
GO:1900158 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of bone mineralization involved in bone maturation. In simpler terms, it encompasses the molecular and cellular events that put the brakes on the deposition of minerals into the bone matrix during the stage when bone is maturing, ensuring that mineralization does not become excessive or occur at the wrong time.
Why Is negative regulation of bone mineralization involved in bone maturation Important in Cell Biology?
GO:1900158 is critically important because it ensures that bone mineralization during maturation is kept within physiological limits. Without proper negative regulation, bones may become overly mineralized and brittle, or mineralization may occur in inappropriate locations, leading to skeletal deformities and increased fracture risk. This process is also central to understanding how systemic factors such as vitamin A, phosphate-regulating hormones like FGF23, and inflammatory signals modulate bone quality. Moreover, disruptions in this regulatory network contribute to metabolic bone diseases, making it a target for therapeutic intervention.
• Prevents hypermineralization and maintains bone flexibility and strength during skeletal maturation.
• Integrates systemic signals (e.g., vitamin A, FGF23) with local bone-forming cell activity.
• Dysregulation is linked to osteoporosis and osteomalacia, major public health burdens.
• Plays a role in the bone defects observed in metabolic disorders such as phenylketonuria.
• Inflammatory conditions can disrupt this process via Notch signaling, affecting osteocyte maturation.
• Provides a mechanistic basis for understanding how osteoblasts balance matrix production and mineralization.
• Offers potential targets for anabolic bone therapies and prevention of ectopic calcification.
• Essential for proper craniofacial and long bone development during growth.
• Helps explain sex- and age-related differences in bone mineral density.
• Guides tissue engineering approaches for bone regeneration by mimicking natural inhibitory cues.
What Happens During negative regulation of bone mineralization involved in bone maturation?
Initiation of negative regulation by systemic and local signals
In simple terms: The body sends signals that tell bone-forming cells to slow down mineral deposition.
Negative regulation of bone mineralization during maturation is initiated by a variety of signals. Vitamin A and its metabolites act as negative regulators of osteoblast mineralization, directly influencing the cells responsible for bone formation. Similarly, fibroblast growth factor 23 (FGF23) inhibits osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, thereby reducing the pool of cells that can mineralize the matrix. Inflammatory macrophages can also interrupt osteocyte maturation and mineralization by regulating the Notch signaling pathway, demonstrating that immune signals participate in this negative regulation.
Transcriptional control of mineralization inhibitors
In simple terms: Certain master switches in the cell turn on genes that block mineralization.
The transcription factor RUNX2 is a key regulator of bone development and maintenance. While it promotes osteoblast differentiation, it also controls the expression of genes that can inhibit mineralization at specific stages, contributing to the negative regulation of bone mineralization involved in bone maturation. The balance of RUNX2 activity and its interaction with cofactors determines whether mineralization proceeds or is restrained. Other transcription factors and signaling pathways, such as those downstream of BMP1/TLD metalloproteinases, may also influence the expression of mineralization inhibitors.
Extracellular matrix remodeling and inhibition of crystal growth
In simple terms: The bone matrix is modified so that minerals cannot grow into large crystals.
Negative regulation of mineralization involves changes in the extracellular matrix that prevent hydroxyapatite crystal growth. Proteins such as HtrA1 serine protease have been implicated in osteoporotic bone extracellular matrix changes, suggesting a role in matrix remodeling that opposes mineralization. Additionally, the activity of BMP1/TLD metalloproteinases, which process procollagen and other matrix proteins, can influence the availability of nucleation sites for mineral deposition. The net effect is a matrix environment that is less permissive for mineralization during bone maturation.
Cellular mechanisms: osteoblast and osteocyte contributions
In simple terms: Bone cells actively stop minerals from being deposited.
Osteoblasts and osteocytes are the primary cells that regulate bone mineralization. Negative regulation can occur through osteoblast-derived factors that inhibit mineral nucleation or promote the expression of mineralization inhibitors. For example, inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass, indicating that AXL signaling normally restrains osteoblast activity and mineralization. Osteocytes, embedded in the mineralized matrix, can also send signals that limit further mineralization, as seen when inflammatory macrophages disrupt osteocyte maturation via Notch. These cellular mechanisms ensure that mineralization is tightly coupled to bone maturation.
Integration with bone maturation stages
In simple terms: The brakes on mineralization are applied at specific times as bone grows.
The negative regulation of bone mineralization is temporally linked to bone maturation. During early stages, mineralization must proceed to establish the skeleton, but as bone matures, inhibitory mechanisms prevent excessive mineralization that could lead to brittleness. This stage-specific control is reflected in the GO term's definition, which explicitly ties the negative regulation to bone maturation. Disruption of this timing can result in pathological conditions such as osteopetrosis or osteomalacia, depending on whether inhibition is lost or enhanced.
Key Genes Involved in GO:1900158 negative regulation of bone mineralization involved in bone maturation
The following genes and proteins have been experimentally implicated in the negative regulation of bone mineralization involved in bone maturation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RUNX2 | Master transcription factor for osteoblast differentiation; can also inhibit mineralization at specific stages | Knockout leads to complete lack of bone; conditional models reveal stage-specific roles |
| FGF23 | Inhibits osteogenic differentiation and mineralization of mesenchymal stem cells | Overexpression causes hypophosphatemic rickets; KO leads to hyperphosphatemia and abnormal mineralization |
| HtrA1 | Serine protease involved in extracellular matrix remodeling; associated with osteoporotic matrix changes | Potential target for modulating bone matrix quality in osteoporosis |
| AXL | Receptor tyrosine kinase that restrains osteoblast function; inhibition increases bone mass | Small molecule inhibitors are being explored for anabolic bone therapy |
| BMP1 | Metalloproteinase that processes procollagen and matrix proteins; influences mineralization | KO models show defects in bone matrix formation and mineralization |
| Notch receptors (e.g., NOTCH1) | Signaling pathway mediating inflammatory macrophage effects on osteocyte maturation and mineralization | Modulators of Notch signaling can alter bone mineralization in inflammatory conditions |
| Vitamin A (retinoic acid) pathway genes (e.g., RARs, RXRs) | Mediate negative regulation of osteoblast mineralization by vitamin A | Dietary or pharmacological manipulation affects bone mass |
| Pah | Phenylalanine hydroxylase; its deficiency in PKU leads to bone mineralization defects via compromised MSC differentiation | Pah(enu2) mouse model recapitulates bone phenotype |
| SP7 (Osterix) | Transcription factor essential for osteoblast differentiation; interacts with RUNX2 | KO lacks bone; overexpression can enhance mineralization |
| SOST (Sclerostin) | Secreted Wnt inhibitor that negatively regulates bone formation and mineralization | Antibody against sclerostin increases bone mass in clinical trials |
| DKK1 | Wnt signaling inhibitor that reduces osteoblast activity and mineralization | Target for osteoporosis therapy |
| MEPE | Matrix extracellular phosphoglycoprotein; inhibits mineralization | KO mice show increased bone mineralization |
| ENPP1 | Generates pyrophosphate, a potent inhibitor of hydroxyapatite crystal growth | Mutations cause ectopic calcification disorders |
| ANKH | Transports pyrophosphate to the extracellular space; inhibits mineralization | Mutations cause craniometaphyseal dysplasia |
| FGF23 co-receptor α-Klotho | Required for FGF23 signaling; modulates phosphate and vitamin D metabolism | KO mice exhibit hyperphosphatemia and abnormal mineralization |
| IL-6 | Inflammatory cytokine that can influence osteoblast and osteocyte function | Blockade reduces bone loss in inflammatory diseases |
| TNF-α | Pro-inflammatory cytokine that inhibits osteoblast differentiation and mineralization | Antagonists used in rheumatoid arthritis to protect bone |
| RANKL | Cytokine that promotes osteoclastogenesis; indirectly affects mineralization by resorbing matrix | Denosumab (anti-RANKL) increases bone density |
How Is negative regulation of bone mineralization involved in bone maturation Regulated?
The negative regulation of bone mineralization involved in bone maturation is controlled by a complex network of systemic hormones, local growth factors, and inflammatory mediators. Vitamin A and its active metabolites (retinoic acid) directly inhibit osteoblast mineralization, likely through nuclear receptor signaling. FGF23, produced by osteocytes, suppresses osteogenic differentiation and mineralization of mesenchymal stem cells, and its action is dependent on the co-receptor α-Klotho. Inflammatory macrophages can interrupt osteocyte maturation and mineralization by activating Notch signaling, revealing a link between the immune system and bone maturation. Additionally, the AXL receptor tyrosine kinase acts as a negative regulator of osteoblast function; its inhibition increases bone mass, suggesting that AXL signaling restrains mineralization. Transcriptionally, RUNX2 coordinates both positive and negative effects on mineralization depending on the stage of osteoblast differentiation and the presence of cofactors. The BMP1/TLD metalloproteinases process extracellular matrix proteins and can influence the availability of mineralization inhibitors such as MEPE and pyrophosphate. Together, these regulatory inputs ensure that mineralization is appropriately restrained during bone maturation.
negative regulation of bone mineralization involved in bone maturation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAH | Phenylketonuria with bone mineralization defects | Pah(enu2) mouse model; patient-derived iPSCs |
| HtrA1 | Osteoporotic bone extracellular matrix changes | HtrA1 knockout mice; osteoblast-specific overexpression |
| ENPP1 | Generalized arterial calcification of infancy; ectopic mineralization | Enpp1 knockout mice; knock-in of patient mutations |
| AXL | Regulation of osteoblast function and bone mass | AXL knockout mice; small molecule inhibitor treatment |
| FGF23 | Hypophosphatemic rickets/osteomalacia; altered mineralization | FGF23 transgenic and knockout mice |
Osteoporosis and osteomalacia
Osteoporosis is characterized by low bone mass and microarchitectural deterioration, often resulting from an imbalance between bone formation and resorption. Impaired negative regulation of mineralization could contribute to excessive mineralization of the remaining matrix, making bone brittle. HtrA1 serine protease has been implicated in osteoporotic bone extracellular matrix changes, suggesting that altered matrix remodeling may affect mineralization control. In osteomalacia, defective mineralization leads to soft bones, highlighting the importance of proper negative regulation to avoid under-mineralization.
Phenylketonuria-associated bone disease
Classical phenylketonuria (PKU) is caused by mutations in the PAH gene, leading to phenylalanine accumulation. The Pah(enu2) mouse model exhibits a bone mineralization defect that involves compromised mesenchymal stem cell differentiation. This suggests that metabolic disturbances can impact the negative regulation of bone mineralization during maturation, contributing to skeletal fragility in PKU patients.
Inflammatory bone diseases
Chronic inflammation, as seen in rheumatoid arthritis, is associated with bone loss and altered mineralization. Inflammatory macrophages can interrupt osteocyte maturation and mineralization via the Notch signaling pathway, potentially disrupting the negative regulation of mineralization. Cytokines such as TNF-α and IL-6 inhibit osteoblast differentiation and mineralization, further linking inflammation to dysregulated bone maturation.
Ectopic calcification disorders
Conditions such as generalized arterial calcification of infancy (GACI) result from mutations in ENPP1, which normally generates pyrophosphate, a potent inhibitor of mineralization. Loss of ENPP1 leads to ectopic calcification, demonstrating that negative regulation of mineralization is critical not only in bone but also in soft tissues. Similarly, mutations in ANKH, which transports pyrophosphate, cause craniometaphyseal dysplasia, a disorder of abnormal bone mineralization.
From negative regulation of bone mineralization involved in bone maturation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase bone mineralization? | CRISPR knockout in osteoblast cell lines (e.g., MC3T3-E1) or conditional knockout mice |
| Does a specific point mutation in a gene affect its inhibitory function? | CRISPR point mutation knock-in in mesenchymal stem cells or mice |
| Does overexpression of a negative regulator reduce mineralization in vivo? | Transgenic overexpression or viral delivery in mouse bone |
| Can we tag an endogenous protein to track its localization during bone maturation? | CRISPR knock-in of fluorescent or epitope tags |
| Which genes are essential for negative regulation in a genome-wide manner? | CRISPR library screening in osteoblast differentiation assays |
| Does a disease-associated variant alter mineralization regulation? | Patient-derived iPSCs with CRISPR correction or introduction of variant |
How to Study the negative regulation of bone mineralization involved in bone maturation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify negative regulators induced during bone maturation |
| ChIP-seq | Transcription factor binding sites | Map RUNX2 targets that inhibit mineralization |
| Proteomics | Protein abundance in matrix/secretome | Discover secreted inhibitors like MEPE, ENPP1 |
| Histology (von Kossa) | Calcium deposits in tissue sections | Assess mineralization in knockout models |
| Micro-CT | Bone mineral density and microarchitecture | Quantify bone mass in transgenic mice |
| CRISPR knockout screen | Gene function on a genome-wide scale | Identify novel negative regulators of mineralization |
| CRISPR activation screen | Gain-of-function effects | Find genes whose overexpression blocks mineralization |
| Live-cell imaging | Dynamic localization of tagged proteins | Track inhibitor recruitment to mineralizing matrix |
Transcriptomic and epigenomic profiling
RNA sequencing (RNA-seq) can identify genes differentially expressed during bone maturation and mineralization. By comparing osteoblasts at different stages or under conditions that promote or inhibit mineralization, researchers can pinpoint negative regulators. Chromatin immunoprecipitation sequencing (ChIP-seq) for RUNX2 and other transcription factors reveals direct targets that mediate negative regulation. Single-cell RNA-seq can uncover heterogeneity in osteoblast populations and identify subpopulations with high inhibitory activity.
Proteomic and secretome analysis
Mass spectrometry-based proteomics of bone matrix or conditioned media from osteoblast cultures can identify proteins that inhibit mineralization, such as MEPE, ENPP1, and HtrA1. Secretome analysis is particularly useful for discovering paracrine factors that negatively regulate mineralization in a non-cell-autonomous manner.
Histological and imaging techniques
Bone mineralization can be assessed using histological staining with von Kossa or Alizarin Red, which detect calcium deposits. Micro-computed tomography (micro-CT) provides quantitative measures of bone mineral density and microarchitecture in animal models. Fluorescence microscopy with tagged proteins can visualize the localization of negative regulators relative to mineralizing fronts.
Functional assays with CRISPR screens
CRISPR knockout screens enable unbiased identification of genes whose loss alters mineralization. For example, a genome-wide screen in osteoblasts treated with mineralization-inducing medium can reveal negative regulators; cells with increased mineralization upon gene knockout are candidates. Similarly, CRISPR activation (CRISPRa) screens can identify genes whose overexpression inhibits mineralization.
How CRISPR Can Be Used to Study GO:1900158 negative regulation of bone mineralization involved in bone maturation
Knockout
CRISPR knockout is used to delete candidate negative regulator genes in osteoblast cell lines or mice. For example, knocking out Axl in osteoblasts increases bone mass, confirming its role as a negative regulator of mineralization. Similarly, knockout of Enpp1 leads to ectopic calcification, demonstrating loss of a mineralization inhibitor. These models help establish causality and provide insights into gene function during bone maturation.
Point Mutation
CRISPR point mutation knock-in introduces specific disease-associated or functional variants into the genome. This is particularly useful for studying how single amino acid changes affect the inhibitory activity of proteins like ENPP1 or ANKH. Point mutations can also be used to disrupt phosphorylation sites or catalytic residues in kinases such as AXL to dissect signaling pathways.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) or epitope tags allows visualization and tracking of endogenous negative regulators. For instance, tagging RUNX2 with a fluorescent protein enables live-cell imaging of its dynamics during osteoblast differentiation. Knock-in of human disease mutations into mouse models, such as the Pah(enu2) mutation, recapitulates bone phenotypes and facilitates drug testing.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression is used to increase the levels of negative regulators. Overexpression of FGF23 in mice leads to hypophosphatemic rickets and impaired mineralization, confirming its inhibitory role. Similarly, overexpression of vitamin A pathway components can suppress osteoblast mineralization. These models are valuable for testing whether enhancing negative regulation can prevent hypermineralization disorders.
How EDITGENE Supports negative regulation of bone mineralization involved in bone maturation Research
Researchers studying negative regulation of bone mineralization involved in bone maturation-related genes often need to determine whether a candidate gene is causally involved in restraining mineralization, and to dissect the precise stage and mechanism of its action. This requires sophisticated genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant bone cells or animal models. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such discoveries, from custom knockout and knock-in cell lines to genome-wide library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of bone mineralization involved in bone maturation research.
Frequently Asked Questions About negative regulation of bone mineralization involved in bone maturation
What is GO:1900158?
GO:1900158 is a Gene Ontology term for the biological process 'negative regulation of bone mineralization involved in bone maturation', which describes any mechanism that reduces or prevents mineral deposition during the maturation phase of bone development.
What genes are involved in negative regulation of bone mineralization involved in bone maturation?
Key genes include RUNX2, FGF23, AXL, HtrA1, ENPP1, ANKH, and components of the vitamin A and Notch signaling pathways.
How does vitamin A inhibit bone mineralization?
Vitamin A metabolites such as retinoic acid act as negative regulators of osteoblast mineralization, likely through nuclear receptor signaling that suppresses genes required for mineral deposition.
What is the role of FGF23 in bone mineralization?
FGF23 inhibits osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, and its overexpression leads to hypophosphatemic rickets with impaired mineralization.
Can CRISPR be used to study bone mineralization?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are widely used to dissect gene function in osteoblasts and animal models, as demonstrated for Axl, Enpp1, and Pah.
What diseases are associated with dysregulated bone mineralization?
Osteoporosis, osteomalacia, phenylketonuria-associated bone defects, and ectopic calcification disorders such as GACI are linked to altered negative regulation of mineralization.
How is bone mineralization measured in the lab?
Common methods include von Kossa and Alizarin Red staining for calcium deposits, micro-CT for bone mineral density, and quantitative PCR or RNA-seq for gene expression.
What is the difference between bone mineralization and negative regulation of bone mineralization?
Bone mineralization is the process of depositing minerals into the bone matrix, while negative regulation of bone mineralization involved in bone maturation specifically refers to the processes that restrain or reduce this deposition during the maturation phase.
Which signaling pathways regulate negative bone mineralization?
The Notch, Wnt, FGF, and vitamin A signaling pathways, as well as inflammatory cytokine pathways, have been implicated in negatively regulating bone mineralization.
How can I create a knockout model for a gene involved in bone mineralization?
EDITGENE provides custom CRISPR knockout services in osteoblast cell lines and mice, including validation and functional assays to confirm effects on mineralization.
Conclusion
GO:1900158, negative regulation of bone mineralization involved in bone maturation, represents a critical biological process that ensures proper skeletal development by restraining mineral deposition at the right time and place. Dysregulation of this process contributes to a range of bone diseases, from osteoporosis to ectopic calcification. Advances in CRISPR-based genetic models and high-throughput screening are rapidly expanding our understanding of the genes and mechanisms involved. EDITGENE offers a comprehensive toolkit to accelerate this research, enabling precise manipulation of candidate genes and pathways in relevant bone models.
References
- 1. Komori T. 2008. Regulation of bone development and maintenance by Runx2.. Front Biosci 13:898-903 PMID: 17981598
- 2. Dobrowolski SF et al.. 2018. A bone mineralization defect in the Pah(enu2) model of classical phenylketonuria involves compromised mesenchymal stem cell differentiation.. Mol Genet Metab 125(3):193-199 PMID: 30201326
- 3. Ge G et al.. 2006. Developmental roles of the BMP1/TLD metalloproteinases.. Birth Defects Res C Embryo Today 78(1):47-68 PMID: 16622848
- 4. Licini C et al.. 2024. Possible involvement of HtrA1 serine protease in the onset of osteoporotic bone extracellular matrix changes.. Tissue Cell 87:102329 PMID: 38367326
- 5. Ahmad M et al.. 2026. Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass.. Bone Res 14(1) PMID: 42409771
- 6. Lind T et al.. 2013. Vitamin a is a negative regulator of osteoblast mineralization.. PLoS One 8(12):e82388 PMID: 24340023
- 7. Wang S et al.. 2022. Inflammatory macrophages interrupt osteocyte maturation and mineralization via regulating the Notch signaling pathway.. Mol Med 28(1):102 PMID: 36058911
- 8. Lyu Z et al.. 2023. Fibroblast growth factor 23 inhibits osteogenic differentiation and mineralization of chicken bone marrow mesenchymal stem cells.. Poult Sci 102(1):102287 PMID: 36442309
